VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2020 | HDAC inhibitors: panobinostat for R/R myeloma

Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, discusses the use of histone deacetylase (HDAC) inhibitors, specifically panobinostat, for the treatment of relapsed/refractory (R/R) multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter